BioTelemetry Inc

Find Ratings Reports
BEAT : NASDAQ : Health Care
$18.66 -0.04 | -0.21%
Today's Range: 18.37 - 18.78
Avg. Daily Volume: 449,300
09/28/16 - 4:00 PM ET

Financial Analysis


BIOTELEMETRY INC's gross profit margin for the second quarter of its fiscal year 2016 has increased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. BIOTELEMETRY INC has strong liquidity. Currently, the Quick Ratio is 1.89 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 31.59% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)52.6844.81
EBITDA ($mil)9.25.63
EBIT ($mil)5.542.62
Net Income ($mil)4.342.17


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)25.4414.8
Total Assets ($mil)156.19119.98
Total Debt ($mil)37.7624.39
Equity ($mil)88.567.25


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin67.5664.17
EBITDA Margin17.4612.56
Operating Margin10.515.86
Sales Turnover1.231.46
Return on Assets8.720.34
Return on Equity15.40.62
Debt Q2 FY16 Q2 FY15
Current Ratio2.071.58
Debt/Capital0.30.27
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)28.0327.08
Div / share0.00.0
EPS0.140.08
Book value / share3.162.48
Institutional Own % n/a n/a
Avg Daily Volume440641.0272769.0

Valuation


BUY. BIOTELEMETRY INC's P/E ratio indicates a significant premium compared to an average of 20.69 for the Health Care Providers & Services industry and a significant premium compared to the S&P 500 average of 25.19. For additional comparison, its price-to-book ratio of 5.89 indicates a significant premium versus the S&P 500 average of 2.82 and a significant premium versus the industry average of 3.14. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, BIOTELEMETRY INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BEAT 40.43 Peers 20.69   BEAT 17.87 Peers 12.71

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

BEAT is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BEAT is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BEAT 22.68 Peers 15.78   BEAT 0.21 Peers 0.85

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

BEAT is trading at a significant premium to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BEAT trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BEAT 5.89 Peers 3.14   BEAT 2200.00 Peers 27.83

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BEAT is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

BEAT is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BEAT 2.72 Peers 0.78   BEAT 9.46 Peers 14.36

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BEAT is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BEAT significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades